State of Hepatitis C- The Nigeria Experience Ghana 12 th August, 2013 Dr. Adegboyega Akere Lecturer/Consultant Physician & Gastroenterologist University.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Presented by Cheri Booth, MPH MN Department of Health November 22, 2013.
Hepatitis C in Retrospect David Gladders Portsmouth City Council.
Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.
Saotharlann Náisiúnta Tagartha Viris UCD UCD National Virus Reference Laboratory Dr. Jeff Connell Assistant Director National Virus Reference Laboratory.
DR SACHIN VERMA MD( MEDICINE),FICM,FCCS CONSULTANT INTERNAL MEDICINE & CRITICAL CARE IVY HOSPITAL MOHALI Hepatitis D.
Liver Disease and Thalassaemia George Constantinou.
Epidemiology of Chronic Hepatitis B virus infection Dr Olufunmilayo Lesi Consultant Physician and Gastroenterologist College of Medicine, University of.
Hepatitis C In Alaska’s Department of Corrections
Epidemiology and Control Programs for HBV Infection. Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Hepatitis C testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Hepatitis C? Hepatitis C is a contagious.
Topic : Hepatitis C. Hepatitis C is an infectious disease of liver which is caused by Hepatitis C virus. It causes the inflammation of liver. Initial.
Hepatitis C.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
HEPATITIS A VIRUS Week Response Clinical illness ALT IgM IgG HAV in stool Infection Viremia EVENTS IN HEPATITIS A VIRUS INFECTION.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
Surveillance of hepatitis C Infection in France JC Desenclos, Département des Maladies Infectieuses Institut de Veille Sanitaire.
Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.
Harold S. Margolis, M.D. Division of Viral Hepatitis
Hepatitis B Virus 28.
Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis D (Delta) Virus Division of Viral Hepatitis.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
Enhanced Hepatitis Strain & Surveillance System (EHSSS) in Review BCCDC Hepatitis Site Site Investigator: Liza McGuinness.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.
Sara Stevenson Hepatitis B Nurse Specialist St James’s Hospital, Leeds.
21/2/ Viral Hepatitis B (HBV) Associate Professor Family and Community Medicine Department King Saud University.
Basic Facts About HIV and AIDS. Presentation Objectives By the end of this session you should be able to:  explain the facts about HIV and AIDS;  describe.
Maruf Aberra(MD) HEPATITIS C VIRUS. Virology RNA virus that belongs to the family flaviviruses; sole member of the genus hepacivirus. Enveloped,
SEIEVA Integrated Epidemiological System for Acute Viral Hepatitis Alfonso Mele Catania, November
The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.
Hepatitis C A Growing Problem of Pakistan. Group Members Zoya Imran Mariam Archer Nawal Nawaz Sidra Tul Muntaha.
Epidemiologic Update: Hepatitis C
Hepatitis D (Delta) Virus
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
Hepatitis C Dr R V S N Sarma., M.D Consultant Physician.
Prevalence of hepatitis B and C viruses among human immunodeficiency virus infected children in Northern Nigeria. Pennap GRI, Yahuza, AJ and Abdulkarim,
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
Parallel and Overlapping Prevalence of Hepatitis B and C Viruses in Apparently Healthy Individuals in a Northern Nigerian Population Pennap, GRI and Chuga,
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
NIMR 6 th Annual Scientific Conference 10TH-12TH Nov. NIMR Auditorium, 6 Edmond Crescent, Yaba, Lagos. NIMR 6 th Annual Scientific Conference 10TH-12TH.
Viral hepatitis overview Itodo Ewaoche 27/02/2015.
Hepatitis A, B, C: Overview, Serologies, and Vaccination Connie Tien June 6, 2016.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Viral Hepatitis.
Hepatitis C.
Hepatitis C: Overview and Epidemiology
Dr. Mohammed Omar Khalifa
MICROBIOLOGY PRACTICAL
PREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG FEDERAL
Knowledge of transmission Sharing of sharp objects
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
Introduction Results Conclusions Methods
Vrushali Patwardhan, Dinesh Kumar, Varun Goel, Sarman Singh
Okonko IO, Mbabie F, Anah EJ*
Higher Prevalence of HbsAg among Blood Donors at a tertiary care center in greater Gwalior: A 5years study ( TTI-12 : D-1182 ) Dr. Anita Arya, Dr. Sachin.
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
History & Epidemiology in Iran
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
By: Antehun Alemayehu (M.Sc)
© The Author(s) Published by Science and Education Publishing.
Presentation transcript:

State of Hepatitis C- The Nigeria Experience Ghana 12 th August, 2013 Dr. Adegboyega Akere Lecturer/Consultant Physician & Gastroenterologist University of Ibadan/University College Hospital, Ibadan, Nigeria

Incidence & Prevalence Worldwide prevalence is 3% North America – 0.4%-1.1% North Africa – 9.6%-13.6% Egypt has the highest prevalence worldwide 9-50%

Prevalence in Nigeria Prevalence among local blood donors in Nigeria ranges from % Inyama et al in Jos found a prevalence of 5.7% among 490 Nigerians with HIV infection A prevalence of 5.0% was observed among sickle cell anaemia patients in Lagos Adewole et al in Abuja found a prevalence of 2.3% among 260 HIV patients

Olokoba et al in Ilorin found a prevalence of 9.3% among 280 patients with DM Pennap et al in Keffi among 113 apparently healthy local community, found a prevalence of 13.2% Chukwurah et al in Enugu found a prevalence of 7.6% among 1280 blood donors Alao et al in Makurdi found a prevalence of 5.4% among 1400 blood donors over 1 year period

Laraba et al in Maiduguri in a study of 90 patients with CLD and 85 controls reported a prevalence of 14.4% and 2.4% respectively Nwokediuko et al in Enugu found a prevalence of 14.1% and 3.7% among 191 diabetics and 134 controls respectively Adegoke et al at Ile-Ife reported a prevalence of 0.8% and 2.2% among 115 diabetics and 2013 controls respectively Balogun et al in Ibadan found a prevalence of 0% and 1.1% among diabetics and controls respectively

Out-patients of the Gastroenterology Clinic UCH, Ibadan Total number HBV infection 257(54.3%) 123(50%) HCV infection 5(1.06%) 5(2.03%)

Results of Screening Exercise Total number of subjects HBsAg - 16 (5.25%) AntiHCV - 1 (0.33%)

Modes of Transmission

Risk Factors for HCV infection Risk Factors Cases (N=90) Controls (N=90) Previous blood transfusion 14 (15.6%) 18 (20.0%) Previous surgical procedure 27 (30.0%) 25 (27.8%) Tattooing 33 (36.7%) 27 (30.0%) Illicit self-injection 12 (13.3%) 14 (15.6%) Multiple sexual partners 6 (6.7%) 0 Exposure to jaundiced subject 13 (14.4%) 14 (15.0%) Dental extraction 32 (35.6%) 22 (24.4%) Scarification 66 (73.3%) 53 (58.9%) Ear piercing 47 (52.2%) 37 (41.1%) Circumcision 42 (46.7%) 39 (43.3%) Uvulectomy (by native doctors) 4 (4.4%) 12 (13.3%) Balogun et al. Low Prevalence of Hepatitis-C Viral Seropositivity among Patients with Type-2 Diabetes Mellitus in a Tertiary Hospital. Journal of the National Medical Association 2006;98:

HCV Genotypes

Global Distribution of HCV Genotypes

HCV Genotypes in Nigeria Oni et al reported at least two major genotypes(1&4) in Nigeria Oni AO,et al. Genotypes of hepatitis C virus in Nigeria. J Med Virol.1996;49: In a study conducted in two rural remote communities in North Central Nigeria (n=519), a prevalence of 15% was reported and the genotypes are: genotype 1(85%), genotype 2 (15%) Forbi JC, et al. Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. Journal of General Virology 2012;93:

Investigations HBsAg, HIV Liver Function Tests Abdominal USS HCV RNA Assay HCV Genotype Full Blood Count

Challenges of Managing HCV Infection Poor knowledge of the importance of the infection by patients and some doctors Practice by quacks who take advantage of patients Equipments for further investigation of patients are not widely available High cost of tests High cost of drugs High cost of managing side effects from the drugs